Navigation Links
Consortium studying mathematical modeling of influenza infection
Date:12/16/2010

Mount Sinai School of Medicine today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has renewed funding of the Program for Research on Immune Modeling and Experimentation (PRIME). This program seeks to develop easy-to-use, predictive mathematical models to better understand patterns of infection among individuals affected by the H1N1 and 1918 influenza viruses and other related viruses.

The renewed contract provides an additional $17.2 million over five years to the initiative, following an initial contract of $16.8 million, bringing the total funding for PRIME to $34 million. Mount Sinai is the primary research site for PRIME, leading five other institutions and organizations around the world.

As part of PRIME, researchers at Mount Sinai School of Medicine use data-based models to simulate the response of human dendritic cells, a type of immune cell, to influenza viruses. The PRIME team will test and refine a cutting-edge informatics platform that replaces paper recordkeeping and transmits results to a centralized database sponsored by NIAID. This database will help scientists more effectively design their experiments and make better use of available data. Under the renewed contract, Mount Sinai researchers will perform large-scale experiments to validate mathematical models and test their predictions, with the goal of helping scientists better understand the immune response to these viruses.

"The number of factors contributing to human response to a virus is overwhelming, far too many for scientists to test through traditional experiments," said Stuart C. Sealfon, MD, Glickenhaus Professor and Chair of the Department of Neurology, Director of the Center for Genomics, Proteomics and Bioinformatics, Director of the Center for Translational Systems Biology, Professor of Neurobiology, and Professor of Pharmacology and Systems Therapeutics at Mount Sinai School of Medicine. "Using a computational approach, we can better understand what makes these viruses tick, allowing scientists to refer to a centralized database to better direct their experiments."

During the first five years of the contract, the PRIME team made several advances in working with immunologists on using these tools. With the renewal, the research team will facilitate the use of computational approaches by experimentalists to elucidate the molecular mechanism of action of virus infection.

"The PRIME team is at the forefront of a major transition in medical research to leverage the power of computational biology to help design experiments," said Dr. Sealfon. "This approach can make these experiments much more efficient and accelerate scientific discovery, which is especially critical in studying severe pandemics."


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related biology news :

1. Missouri Botanical Garden joins convention on biological diversity consortium of scientific partners
2. International malaria research consortium tackles deadly disease
3. NSF awards $3.75 million grant to New York Plant Genome Consortium for the creation of BigPlant v1.0
4. Consortium to design human trials of mosaic HIV vaccine
5. Aeras-led research consortium receives FDA support
6. Structural Genomics Consortium releases 1,000th protein structure
7. Aware to Introduce Several New Software Products at the Biometrics Consortium Conference
8. AOptix Technologies to Show Combined Biometric Face and Iris Capture System at Biometrics Consortium Conference
9. DOE awards UC San Diego consortium $9 million for algal biofuels research
10. WHOI joins consortium to study, minimize effects of Gulf Oil spill
11. Biomedical research infrastructure goes global: EU consortium Infrafrontier has new partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a medical ... (IV) therapy, today announced receipt of its ISO 13485 Certification, the ... the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection ... "This is an important ...
(Date:7/20/2017)... 20, 2017 Delta (NYSE: DAL ) customers now ... aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at ... Delta,s biometric boarding pass experience ... is now integrated into the boarding process to allow eligible Delta SkyMiles ...
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... ... August 16, 2017 , ... ... a different cell type. Many treatments for specific cancers, such as breast, prostate, ... targeted treatment is androgen deprivation therapy for advanced prostate cancer. , This ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... third U.S. Food and Drug Administration (FDA) inspection at our Dilworth, MN site. ... 483 was issued. This inspection was conducted as part of a routine Bioresearch ...
(Date:8/15/2017)... -- After spending the past two years building a state-of-the-art technology ... now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies ... data collection vis a vis their members, under their own brand. ... this offer. ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... largest Asian exhibitions for analytical and scientific instruments. This year’s symposium, organized by ... Approaches in Mass Spectrometry for Bioanalytical Applications.” This dynamic presentation will discuss novel ...
Breaking Biology Technology: